{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T23:50:10Z","timestamp":1785714610362,"version":"3.56.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.gastha.2025.100812","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T03:33:56Z","timestamp":1758080036000},"page":"100812","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Once-Daily Oral Ozanimod for Japanese Patients With Ulcerative Colitis: Results From the Phase 2\/3 J-True North Study"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2848-6586","authenticated-orcid":false,"given":"Hiroshi","family":"Nakase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimitsu","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadakazu","family":"Hisamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakuma","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuguhiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Furuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenkei","family":"Hasatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Horiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Kanke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoki","family":"Tokito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souken","family":"Sai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Uchikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichiro","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AnnKatrin","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Hibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastha.2025.100812_bib1","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG Clinical Guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastha.2025.100812_bib2","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/bph.13476","article-title":"Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity","volume":"173","author":"Scott","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.gastha.2025.100812_bib3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00384-023-04417-6","article-title":"Trends in the prevalence and incidence of ulcerative colitis in Japan and the US","volume":"38","author":"Yamazaki","year":"2023","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.gastha.2025.100812_bib4","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","article-title":"Evidence-based clinical practice guidelines for inflammatory bowel disease 2020","volume":"56","author":"Nakase","year":"2021","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.gastha.2025.100812_bib5","series-title":"\"CAROGRA\u00ae tablets\", approved in Japan for treatment of ulcerative colitis - the world-first orally available \u03b14 integrin antagonist [press release]","year":"2022"},{"key":"10.1016\/j.gastha.2025.100812_bib6","article-title":"The efficacy of currently licensed biologics for treatment of ulcerative colitis: a literature review","volume":"15","author":"Awan","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.gastha.2025.100812_bib7","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/apt.14334","article-title":"A multi-centre audit of excess steroid use in 1176 patients with inflammatory bowel disease","volume":"46","author":"Selinger","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastha.2025.100812_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158017","article-title":"Corticosteroid use and complications in a US inflammatory bowel disease cohort","volume":"11","author":"Waljee","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.gastha.2025.100812_bib9","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/ibd\/izab016","article-title":"Ulcerative colitis narrative global survey findings: the impact of living with ulcerative colitis-patients' and physicians' view","volume":"27","author":"Dubinsky","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastha.2025.100812_bib10","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.gastha.2025.100812_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/17562848231159452","article-title":"Is there an optimal sequence of biologic therapies for inflammatory bowel disease?","volume":"16","author":"Bressler","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.gastha.2025.100812_bib12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2025.100812_bib13","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastha.2025.100812_bib14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40265-023-01840-5","article-title":"Safety of Janus kinase inhibitors in inflammatory bowel diseases","volume":"83","author":"N\u00fa\u00f1ez","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.gastha.2025.100812_bib15","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/jcm9010094","article-title":"Ulcerative colitis: current and emerging treatment strategies","volume":"9","author":"Kayal","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.gastha.2025.100812_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/17562848221102283","article-title":"Targeting IL12\/23 in ulcerative colitis: update on the role of ustekinumab","volume":"15","author":"Pugliese","year":"2022","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.gastha.2025.100812_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103329","article-title":"Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: current and novel biomarkers","volume":"66","author":"Cui","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.gastha.2025.100812_bib18","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.gastha.2025.100812_bib19","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.3390\/jcm12155014","article-title":"Efficacy and safety of S1P1 receptor modulator drugs for patients with moderate-to-severe ulcerative colitis","volume":"12","author":"Bencardino","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.gastha.2025.100812_bib20","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod induction and maintenance treatment for ulcerative colitis","volume":"374","author":"Sandborn","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastha.2025.100812_bib21","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s40265-021-01528-8","article-title":"Targeting sphingosine-1-phosphate signaling in immune-mediated diseases: beyond multiple sclerosis","volume":"81","author":"P\u00e9rez-Jeldres","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.gastha.2025.100812_bib22","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastha.2025.100812_bib23","series-title":"U.S. Food and Drug Administration approves Bristol Myers Squibb\u2019s ZEPOSIA\u00ae (ozanimod), a new oral treatment for relapsing forms of multiple sclerosis [press release]","author":"Bristol Myers","year":"2020"},{"key":"10.1016\/j.gastha.2025.100812_bib24","series-title":"Zeposia [package insert]","year":"2024"},{"key":"10.1016\/j.gastha.2025.100812_bib25","series-title":"Zeposia [summary of product characteristics]","year":"2024"},{"key":"10.1016\/j.gastha.2025.100812_bib26","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1177\/10600280211041907","article-title":"Ozanimod: a first-in-class sphingosine 1-phosphate receptor modulator for the treatment of ulcerative colitis","volume":"56","author":"Choi","year":"2022","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.gastha.2025.100812_bib27","series-title":"Bristol Myers Squibb receives European Commission approval of Zeposia (ozanimod) for use in adults with moderately to severely active ulcerative colitis","author":"Bristol Myers","year":"2021"},{"key":"10.1016\/j.gastha.2025.100812_bib28","series-title":"Bristol Myers Squibb receives European Commission approval for Zeposia (ozanimod) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease [press release]","author":"Bristol Myers","year":"2020"},{"key":"10.1016\/j.gastha.2025.100812_bib29","series-title":"Zeposia Japanese [package insert]","year":"2024"},{"key":"10.1016\/j.gastha.2025.100812_bib30","series-title":"Guidance for Industry: Drug-induced liver injury: premarketing clinical evaluation","year":"2009"},{"key":"10.1016\/j.gastha.2025.100812_bib31","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial","volume":"18","author":"Cohen","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.gastha.2025.100812_bib32","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.gastha.2025.100812_bib33","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40265-020-01431-8","article-title":"Sphingosine 1-phosphate receptor modulator therapy for multiple sclerosis: differential downstream receptor signalling and clinical profile effects","volume":"81","author":"Chun","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.gastha.2025.100812_bib34","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/jcph.887","article-title":"Results from the first-in-human study with ozanimod, a novel, selective sphingosine-1-phosphate receptor modulator","volume":"57","author":"Tran","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.gastha.2025.100812_bib35","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/ecco-jcc\/jjad146","article-title":"Efficacy and safety of approximately 3 years of continuous ozanimod in moderately to severely active ulcerative colitis: interim analysis of the True North open-label extension","volume":"18","author":"Danese","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastha.2025.100812_bib36","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1093\/ibd\/izy131","article-title":"Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib","volume":"24","author":"Winthrop","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastha.2025.100812_bib37","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13075-016-0932-2","article-title":"Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study","volume":"18","author":"Yamanaka","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.gastha.2025.100812_bib38","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00296-022-05270-6","article-title":"Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies","volume":"43","author":"Gialouri","year":"2023","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.gastha.2025.100812_bib39","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000839","article-title":"Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS","volume":"7","author":"Harris","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.gastha.2025.100812_bib40","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1007\/s10620-024-08391-z","article-title":"Ozanimod differentially impacts circulating lymphocyte subsets in patients with moderately to severely active Crohn's disease","volume":"69","author":"Harris","year":"2024","journal-title":"Dig Dis Sci"},{"issue":"1 suppl","key":"10.1016\/j.gastha.2025.100812_bib41","first-page":"93","article-title":"A post hoc analysis of immunoglobulin levels in patients with relapsing multiple sclerosis treated with ozanimod in phase 3 trials [abstract P159]","volume":"28","author":"Harris","year":"2022","journal-title":"Mult Scler J"},{"key":"10.1016\/j.gastha.2025.100812_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102844","article-title":"Ozanimod in relapsing multiple sclerosis: pooled safety results from the clinical development program","volume":"51","author":"Selmaj","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.gastha.2025.100812_bib43","series-title":"Zeposia assessment report","year":"2020"},{"key":"10.1016\/j.gastha.2025.100812_bib44","doi-asserted-by":"crossref","first-page":"275","DOI":"10.5217\/ir.2020.00002","article-title":"NUDT15 gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease","volume":"18","author":"Matsuoka","year":"2020","journal-title":"Intest Res"},{"key":"10.1016\/j.gastha.2025.100812_bib45","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s40262-024-01393-0","article-title":"Innovating thiopurine therapeutic drug monitoring: a systematic review and meta-analysis on DNA-thioguanine nucleotides (DNA-TG) as an inclusive biomarker in thiopurine therapy","volume":"63","author":"Bayoumy","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.gastha.2025.100812_bib46","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.4049\/jimmunol.160.10.5037","article-title":"FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing","volume":"160","author":"Chiba","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.gastha.2025.100812_bib47","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.4049\/jimmunol.164.11.5761","article-title":"FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory","volume":"164","author":"Pinschewer","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.gastha.2025.100812_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-38952-7","article-title":"Loss of Nudt15 thiopurine detoxification increases direct DNA damage in hematopoietic stem cells","volume":"13","author":"Yamashita","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.gastha.2025.100812_bib49","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","article-title":"AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis","volume":"167","author":"Singh","year":"2024","journal-title":"Gastroenterology"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572325001992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572325001992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T10:12:51Z","timestamp":1767953571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772572325001992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2772572325001992"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2025.100812","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Once-Daily Oral Ozanimod for Japanese Patients With Ulcerative Colitis: Results From the Phase 2\/3 J-True North Study","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2025.100812","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}],"article-number":"100812"}}